1211 related articles for article (PubMed ID: 17391647)
21. Synthesis of rotenoid derivatives with cytotoxic and topoisomerase II inhibitory activities.
Sangthong S; Krusong K; Ngamrojanavanich N; Vilaivan T; Puthong S; Chandchawan S; Muangsin N
Bioorg Med Chem Lett; 2011 Aug; 21(16):4813-8. PubMed ID: 21741833
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
23. Antitumor agents. Part 230: C4'-esters of GL-331 as cytotoxic agents and DNA topoisomerase II inhibitors.
Han S; Xiao Z; Bastow KF; Lee KH
Bioorg Med Chem Lett; 2004 Jun; 14(11):2979-82. PubMed ID: 15125972
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds.
Janočková J; Plšíková J; Kašpárková J; Brabec V; Jendželovský R; Mikeš J; Kovaľ J; Hamuľaková S; Fedoročko P; Kuča K; Kožurková M
Eur J Pharm Sci; 2015 Aug; 76():192-202. PubMed ID: 25960253
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of pyrroloiminoquinone derivatives.
Passarella D; Belinghieri F; Scarpellini M; Pratesi G; Zunino F; Gia OM; Via LD; Santoro G; Danieli B
Bioorg Med Chem; 2008 Mar; 16(5):2431-8. PubMed ID: 18077173
[TBL] [Abstract][Full Text] [Related]
26. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
27. Rational design of acridine-based ligands with selectivity for human telomeric quadruplexes.
Sparapani S; Haider SM; Doria F; Gunaratnam M; Neidle S
J Am Chem Soc; 2010 Sep; 132(35):12263-72. PubMed ID: 20718414
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
Nacro K; Zha CC; Guzzo PR; Jason Herr R; Peace D; Friedrich TD
Bioorg Med Chem; 2007 Jun; 15(12):4237-46. PubMed ID: 17418582
[TBL] [Abstract][Full Text] [Related]
29. Structure-activity studies with cytotoxic anthrapyrazoles.
Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
[TBL] [Abstract][Full Text] [Related]
30. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
31. Antitumor polycyclic acridines. Part 12. Physical and biological properties of 8,13-diethyl-6-methylquino[4,3,2-kl]acridinium iodide: a lead compound in anticancer drug design.
Missailidis S; Stanslas J; Modi C; Ellis MJ; Robins RA; Laughton CA; Stevens MF
Oncol Res; 2002; 13(3):175-89. PubMed ID: 12549627
[TBL] [Abstract][Full Text] [Related]
32. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
[TBL] [Abstract][Full Text] [Related]
33. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
34. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis.
Chen Z; Liang X; Zhang H; Xie H; Liu J; Xu Y; Zhu W; Wang Y; Wang X; Tan S; Kuang D; Qian X
J Med Chem; 2010 Mar; 53(6):2589-600. PubMed ID: 20170164
[TBL] [Abstract][Full Text] [Related]
35. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
36. 4-Hydroxymethyl-3-aminoacridine derivatives as a new family of anticancer agents.
Charmantray F; Demeunynck M; Carrez D; Croisy A; Lansiaux A; Bailly C; Colson P
J Med Chem; 2003 Mar; 46(6):967-77. PubMed ID: 12620073
[TBL] [Abstract][Full Text] [Related]
37. Benzothiopyranoindole-based antiproliferative agents: synthesis, cytotoxicity, nucleic acids interaction, and topoisomerases inhibition properties.
Dalla Via L; Magno SM; Gia O; Marini AM; Da Settimo F; Salerno S; La Motta C; Simorini F; Taliani S; Lavecchia A; Di Giovanni C; Brancato G; Barone V; Novellino E
J Med Chem; 2009 Sep; 52(17):5429-41. PubMed ID: 19725581
[TBL] [Abstract][Full Text] [Related]
38. Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells.
Kim D; Lee IS; Jung JH; Lee CO; Choi SU
Anticancer Res; 1999; 19(5B):4085-90. PubMed ID: 10628358
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Tanabe K; Ikegami Y; Ishida R; Andoh T
Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204
[TBL] [Abstract][Full Text] [Related]
40. Solid phase combinatorial synthesis of benzothiazoles and evaluation of topoisomerase II inhibitory activity.
Choi SJ; Park HJ; Lee SK; Kim SW; Han G; Choo HY
Bioorg Med Chem; 2006 Feb; 14(4):1229-35. PubMed ID: 16242334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
